Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• B-RAF mutations are frequent in human cancers, particularly melanoma.
• Melanoma tumors with oncogenic BRAF mutations rely on the RAF/MEK/ERK signaling pathway.
• Targeting B-RAF kinase activity offers a therapeutic strategy for melanoma patients.

Purpose of the Study:

• To describe the structure-guided discovery of PLX4032 (RG7204), a potent B-RAF kinase inhibitor.
• To evaluate the preclinical efficacy and safety of PLX4032.
• To assess the clinical activity of PLX4032 in patients with metastatic melanoma.

Main Methods:

• Structure-guided drug design and synthesis of PLX4032.
• Preclinical testing in BRAF-mutant cancer cell lines and xenografts.
• Phase 1 clinical trials with crystalline and amorphous formulations of PLX4032.
• Monitoring of ERK phosphorylation in patient tumor biopsies.

Main Results:

• PLX4032 selectively inhibited the RAF/MEK/ERK pathway in BRAF-mutant cells and reduced tumor size in xenografts.
• Early clinical trials showed ERK pathway inhibition but limited tumor regression with a crystalline formulation.
• An amorphous formulation achieved higher drug exposure, leading to >80% ERK phosphorylation inhibition and clinical response.
• An 81% response rate was observed in metastatic melanoma patients treated with 960 mg twice daily of the amorphous formulation.

Conclusions:

• BRAF-mutant melanomas are highly dependent on B-RAF kinase activity.
• PLX4032 is a potent and selective inhibitor of oncogenic B-RAF kinase.
• Optimized drug formulation and exposure are critical for achieving clinical efficacy in BRAF-mutant melanoma.